DGAP-News: SYGNIS AG

PRESS RELEASE
6 December 2017
/

SYGNIS AG launches TruePrime(TM) apoptotic cell free DNA amplification kit for the liquid biopsy market

- TruePrime(TM) cfDNA kit offers superior selectivity and preferential amplification

- Liquid biopsy market is a fast-growing multibillion market

- TruePrime(TM) cfDNA is fully scalable from small to mid-scale programs

Heidelberg, Germany and Cambridge, UK, 6 December 2017 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced the launch of its TruePrime(TM) apoptotic cell free DNA amplification kit, under the Expedeon brand. The kit enables accurate DNA amplification using cell free DNA (cfDNA) obtained from plasma, serum, urine, cerebrospinal fluid (CSF), or many other bodily fluids.

Dr. Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: "This new TruePrime(TM) apoptotic cell free DNA amplification kit launch comes at a very important period in the growing liquid biopsy market, as applications for the liquid biopsy market will become an important growth driver for Sygnis. The technology contains the latest advances in amplification techniques, sensitivity and simplicity. The addition of this kit to our portfolio supports our contribution to the global effort to discover the genetic cancer markers, which are vital for successful treatments and cures. Additionally, we are further strengthening our IP position around this technology and process."

The TruePrime(TM) apoptotic cell free DNA amplification kit uses a novel multiple displacement amplification method to overcome the common limitations with the analysis of bodily fluid for cell free DNA analysis. By exponentially amplifying cell-free DNA derived from apoptosis, the cell-death mechanism, these TruePrime^TM kits provide users with excellent sensitivity, error-free amplification in high yields and a streamlined workflow for reduced hands-on time.

The new technology expands the Company's range of TruePrime(TM) kits, further strengthening its offering within the growing liquid biopsy market, which is set to increase at a CAGR of 23% by 2022. Kits and consumables are the leading sub-segment to the global liquid biopsy market value. Key factors driving this market include the demand for the detection and monitoring of cancer, which is increasing alongside disease prevalence. The new technology has potential to meet this demand through its use in Next Generation Sequencing (NGS)-based clinical diagnostics.

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About SYGNIS AG: www.sygnis.com

SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon, Innova Biosciences and C.B.S. Scientific brands. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###